arrow
A

Alessia Ciancio

a.o.u. città della salute e della scienza di torino
H指数:32
被引数:3,777

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study

基线HDV-RNA水平可在肝硬化前但不在肝硬化后分层临床风险:一项多中心欧洲研究

2026-04-200
PRE
Burden of Hepatitis D Virus infection in Italy: final results from the HDV Describe study
2025-03-010
PRE
Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study
2025-02-120
OAAI
Autoimmunity in chronic HDV infection: results from the HDV Describe study cohort
2025-02-010
PRE
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA

开发和验证基于pivka-ii的HCV相关肝硬化患者HCC风险分层模型成功治疗DAA

2024-11-212
OAAI
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration
2024-09-280
OAAI
YSafety of direct-acting antivirals for Hepatitis C infection and direct oral anticoagulants co-administration: an Italian multicentric study
2024-02-010
PRE
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort

预测HCV根除后新生门静脉血栓形成: 正在进行的PITER队列中的长期竞争风险分析

2023-11-304
OAAI
Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis
2022-10-293
OAAI
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy
2022-03-152
OAAI